Abmaxis Achieves Milestone in Collaboration With Merck
News Oct 19, 2005
Abmaxis, Inc. has announced that it has achieved a major milestone under its collaboration agreement with Merck & Co., Inc.
Under the terms of the agreement, Abmaxis was to optimize an undisclosed Merck human monoclonal antibody for potential therapeutic use.
The Abmaxis team has re-engineered Merck's human monoclonal antibody and improved antibody affinity 70-fold while retaining its specificity, triggering a milestone payment from Merck.
“It has been a rewarding experience for the Abmaxis team to work with Merck on this technically challenging project and this achievement demonstrates the advantages of our Abmaxis in-silico Immunization (AISIM™) technology platform over conventional antibody engineering technologies,” said Peter Luo, Ph.D., Chief Technology Officer of Abmaxis.
“The results we were able to achieve for Merck are an important validation of our structure-centric approach towards antibody engineering,” added Shirley Clayton, President and Chief Executive Officer.
“It would be a challenge to the conventional sequence-centric antibody engineering approach to achieve such a significant improvement.”
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018